首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1547376

全球溶瘤病毒免疫療法市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Oncolytic Virus Immunotherapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球溶瘤病毒免疫治療市場需求預計將從2023年的1.6635億美元達到近9.756億美元的市場規模，2024-2032年研究期間的複合年成長率為21.72%。

溶瘤病毒免疫療法涉及針對特定癌細胞進行感染和破壞的基因改造病毒，同時刺激抗腫瘤免疫反應。這些溶瘤病毒被設計為在癌細胞內複製，導致細胞裂解並釋放腫瘤抗原，激活免疫系統以瞄準並消除剩餘的癌細胞。這種方法直接減輕腫瘤負擔並增強人體對癌症的自然免疫反應。它正在針對各種癌症進行探索，為化療和放療等傳統療法提供有希望的補充治療，並有可能提高療效並減少副作用。

市場動態

全球癌症發生率不斷上升，對創新和有效的治療方案產生了顯著需求，而溶瘤病毒免疫療法成為一種有前途的方法。基因工程和病毒學的進步使得能夠開發出更有效、更有針對性的溶瘤病毒，從而提高其治療功效和安全性。此外，人們越來越認知到並接受免疫療法作為一種可行的癌症治療方法，這也促進了溶瘤病毒療法的採用。製藥公司和研究機構對研發的大力投資正在加速這些療法的臨床試驗和商業化。突破性療法的監管支持和快速批准正在進一步推動市場成長。

溶瘤病毒刺激針對癌細胞的強大免疫反應的能力，加上它們與檢查點抑制劑和傳統療法等其他治療方法一起使用的潛力，正在推動其臨床應用。此外，生物技術公司和學術機構之間的合作和夥伴關係促進創新並擴大治療管道。個人化醫療的整體推動力，即根據患者個別情況量身訂做治療方案，也支持了溶瘤病毒免疫治療市場的成長。然而，潛在的安全問題、高昂的開發成本以及臨床試驗和法規核准的複雜性可能會阻礙溶瘤病毒免疫療法市場未來幾年的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球溶瘤病毒免疫治療市場的每個細分市場進行了包容性評估。溶瘤病毒免疫治療市場行業的成長和趨勢為本研究提供了整體方法。

市場區隔

溶瘤病毒免疫治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按類型

單純皰疹病毒
痘苗病毒
腺病毒
呼腸孤病毒
其他

依給藥途徑

瘤內
靜脈

按申請

黑色素瘤
非小細胞肺癌（NSCLC）
胰腺癌
乳癌
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲溶瘤病毒免疫治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。溶瘤病毒免疫治療市場的主要參與者包括 Merck & Co. Inc. (Viralytics Limited)、Amgen Inc.、上海3D生物科技有限公司、TILT Biotherapeutics、Oncorus Inc.、Replimune Group Inc.、Oncolys Biopharma Inc.、 Sorrento Therapeutics Inc.、Oncolytics Biotech Inc.、SillaJen Inc.。產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：溶瘤病毒免疫治療市場公司的競爭格局

溶瘤病毒免疫治療市場市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Merck & Co. Inc. (Viralytics Limited)

公司概況
公司收入
產品
最新動態

Amgen Inc.

公司概況
公司收入
產品
最新動態

Shanghai Sunway Biotech Co. Ltd.

公司概況
公司收入
產品
最新動態

TILT Biotherapeutics

公司概況
公司收入
產品
最新動態

Oncorus Inc.

公司概況
公司收入
產品
最新動態

Replimune Group Inc.

公司概況
公司收入
產品
最新動態

Oncolys Biopharma Inc.

公司概況
公司收入
產品
最新動態

Sorrento Therapeutics Inc.

公司概況
公司收入
產品
最新動態

Oncolytics Biotech Inc.

公司概況
公司收入
產品
最新動態

SillaJen Inc

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11215755

The global demand for Oncolytic Virus Immunotherapy Market is presumed to reach the market size of nearly USD 975.6 Million by 2032 from USD 166.35 Million in 2023 with a CAGR of 21.72% under the study period 2024-2032.

Oncolytic virus immunotherapy involves genetically modified viruses that target specific cancer cells for infection and destruction of cancer cells while stimulating an anti-tumor immune response. These oncolytic viruses are engineered to replicate within cancer cells, causing cell lysis and releasing tumor antigens, activating the immune system to target and eliminate remaining cancer cells. This approach directly reduces tumor burden and enhances the body's natural immune response against cancer. It is being explored for various cancers, offering a promising complementary treatment to traditional therapies like chemotherapy and radiation, with the potential for improved efficacy and reduced side effects.

MARKET DYNAMICS

The increasing incidence of cancer worldwide has generated a notable demand for innovative and effective treatment options, with oncolytic virus immunotherapy emerging as a promising approach. Genetic engineering and virology advancements have enabled the development of more potent and targeted oncolytic viruses, enhancing their therapeutic efficacy and safety profile. Additionally, growing awareness and acceptance of immunotherapy as a viable cancer treatment are boosting the adoption of oncolytic virus therapies. Robust investment in research and development by pharmaceutical companies and research institutions is accelerating these therapies' clinical trials and commercialization. Regulatory support and fast-tracked approvals for breakthrough therapies are further propelling market growth.

The ability of oncolytic viruses to stimulate a robust immune response against cancer cells, combined with their potential to be used with other treatments, such as checkpoint inhibitors and traditional therapies, is driving their clinical application. Furthermore, collaborations and partnerships between biotech companies and academic institutions foster innovation and expand the therapeutic pipeline. The overall drive towards personalized medicine, where treatments are tailored to individual patient profiles, also supports the growth of the oncolytic virus immunotherapy market. However, potential safety concerns, high development costs, and the complexity of clinical trials and regulatory approvals may hinder the growth of the oncolytic virus immunotherapy market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Oncolytic Virus Immunotherapy Market. The growth and trends of Oncolytic Virus Immunotherapy Market industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Oncolytic Virus Immunotherapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Herpes Simplex Virus
Vaccinia Virus
Adenovirus
Reovirus
Others

By Route of Administration

Intratumoral
Intravenous

By Application

Melanoma
Non-small Cell Lung Cancer (NSCLC)
Pancreatic Cancer
Breast Cancer
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Oncolytic Virus Immunotherapy Market market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Oncolytic Virus Immunotherapy market include Merck & Co. Inc. (Viralytics Limited), Amgen Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics, Oncorus Inc., Replimune Group Inc., Oncolys Biopharma Inc., Sorrento Therapeutics Inc., Oncolytics Biotech Inc., SillaJen Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data Analysis By Type
5.3. Herpes Simplex Virus Historic and Forecast Sales By Regions
5.4. Vaccinia Virus Historic and Forecast Sales By Regions
5.5. Adenovirus Historic and Forecast Sales By Regions
5.6. Reovirus Historic and Forecast Sales By Regions
5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Intratumoral Historic and Forecast Sales By Regions
6.4. Intravenous Historic and Forecast Sales By Regions

7. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data Analysis By Application
7.3. Melanoma Historic and Forecast Sales By Regions
7.4. Non-small Cell Lung Cancer (NSCLC) Historic and Forecast Sales By Regions
7.5. Pancreatic Cancer Historic and Forecast Sales By Regions
7.6. Breast Cancer Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET COMPANIES

9.1. Oncolytic Virus Immunotherapy Market Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Merck & Co. Inc. (Viralytics Limited)
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Amgen Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Shanghai Sunway Biotech Co. Ltd.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. TILT Biotherapeutics
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Oncorus Inc.
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Replimune Group Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Oncolys Biopharma Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Sorrento Therapeutics Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Oncolytics Biotech Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. SillaJen Inc
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments